INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice. - Leleu X; Lee HC; Zonder JA; Macro M; Ramasamy K; Hulin C; Silar J; Kuhn M; Ren K; Bent-Ennakhil N; Cherepanov D; Stull DM; et al. (Future oncology (London, England), 2024)